Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 2/20 | 0.57 |
| ▸ | RAF1 | P04049 | 2/20 | 0.57 |
| ▸ | LYN | P07948 | 2/20 | 0.57 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.57 |
| ▸ | EGFR | P00533 | 1/20 | 0.57 |
| ▸ | BRAF | P15056 | 1/20 | 0.57 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.57 |
| ▸ | EPHA3 | P29320 | 1/20 | 0.57 |
| ▸ | AKT1 | P31749 | 1/20 | 0.57 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.55 |
| ▸ | SRC | P12931 | 1/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.35 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.35 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.35 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.35 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5753770 | 0.94 | MAPK14 (0.52) | ABL1RAF1LYNMAPK9EGFR | |
| SCHEMBL5782135 | 0.89 | MAPK14 (0.54) | ABL1RAF1LYNMAPK9EGFR | |
| SCHEMBL5754192 | 0.88 | MAPK14 (0.55) | ABL1RAF1LYNMAPK9EGFR | |
| SCHEMBL5753105 | 0.87 | MAPK14 (0.56) | ABL1RAF1LYNMAPK9EGFR | |
| SCHEMBL5753008 | 0.86 | MAPK14 (0.56) | ABL1RAF1LYNMAPK9EGFR | |
| SCHEMBL5754152 | 0.86 | MAPK14 (0.55) | ABL1RAF1LYNMAPK9EGFR | |
| SCHEMBL5753571 | 0.85 | MAPK14 (0.52) | ABL1RAF1LYNMAPK9EGFR | |
| SCHEMBL5755374 | 0.85 | MAPK14 (0.56) | ABL1RAF1LYNMAPK9EGFR | |
| SCHEMBL5753855 | 0.85 | MAPK14 (0.51) | ABL1RAF1LYNMAPK9EGFR | |
| SCHEMBL5752535 | 0.83 | MAPK14 (0.65) | ABL1RAF1LYNMAPK9EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1414810-B1 | 1,4-DISUBSTITUTED BENZO-FUSED CYCLOALKYL UREA COMPOUNDS | BOEHRINGER INGELHEIM PHARMA (US) | 2006-08-30 | — | — | EP | claimed |
| JP-2004534787-A | — | — | 2004-11-18 | — | — | JP | claimed |
| EP-1414810-A2 | 1,4-DISUBSTITUTED BENZO-FUSED CYCLOALKYL UREA COMPOUNDS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-05-06 | — | — | EP | claimed |
| US-20030100608-A1 | 1,4-disubstituted benzo-fused cycloalkyl urea compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-05-29 | — | — | US | claimed |
| WO-2002098869-A2 | 1,4-DISUBSTITUTED BENZO-FUSED CYCLOALKYL UREA COMPOUNDS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2002-12-12 | — | — | WO | claimed |
| EP-1414810-B1 | 1,4-DISUBSTITUTED BENZO-FUSED CYCLOALKYL UREA COMPOUNDS | BOEHRINGER INGELHEIM PHARMA (US) | 2006-08-30 | — | — | EP | disclosed |
| EP-1414810-A2 | 1,4-DISUBSTITUTED BENZO-FUSED CYCLOALKYL UREA COMPOUNDS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-05-06 | — | — | EP | disclosed |
| US-6720321-B2 | REACTING THE ALDEHYDE WITH CARBETHOXYMETHYLENE TRIPHENYLYPHOSPHORANE TO FORM UNSATURATED ESTER, REACTING ESTER WITH DIAZOMETHANE IN PRESENCE OF PALLADIUM ACETATE TO FORM CYCLOPROPANE CABROXYLIC ESTER, HYDROLYSIS TO FORM ACID | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-04-13 | — | — | US | disclosed |
| WO-2002098869-A2 | 1,4-DISUBSTITUTED BENZO-FUSED CYCLOALKYL UREA COMPOUNDS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100608-A1 | 1,4-disubstituted benzo-fused cycloalkyl urea compounds | MPO, NFKBIA, YBX1 | ABL1 2742/4885RAF1 2720/4885LYN 1614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.